DNA

Clairity Appoints Jeffrey R. Luber CEO as Firm Prepares for Global Expansion

Company Poised to Revolutionize Breast Cancer Screening through AI-based Risk Prediction BOSTON, Nov. 5, 2024 /PRNewswire/ -- Clairity, Inc., a…

1 year ago

Complete Genomics Highlights Innovation with Expanded Multi-Omics and Spatial Transcriptomics Applications at ASHG 2024

DENVER, Nov. 4, 2024 /PRNewswire/ -- At the American Society of Human Genetics (ASHG) Annual Meeting (Nov. 5-9, 2024), Complete…

1 year ago

Lonza’s Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studiesCollaboration underscores Lonza's commitment to…

1 year ago

OccuPro Launches Return to Work Software Version 4.0

Setting New Standards in Workers' Compensation DocumentationKENOSHA, WI / ACCESSWIRE / November 4, 2024 / OccuPro, a leader in industrial…

1 year ago

Pioneering Scientist David Deamer to receive ABRF Award for Outstanding Contributions to Biomolecular Technologies

 LEXINGTON, Ky. , Nov. 2, 2024 /PRNewswire/ -- The Association of Biomolecular Resource Facilities (ABRF) is pleased to announce the selection…

1 year ago

Wasatch BioLabs and Oxford Nanopore Team Up to Accelerate Methylation Sequencing Towards Clinical Use

SALT LAKE CITY and OXFORD, United Kingdom, Nov. 1, 2024 /PRNewswire/ -- Wasatch Biolabs (WBL), a disruptive R&D and high-throughput…

1 year ago

Illumina to preview newest innovations in NGS and multiomic technologies at the American Society of Human Genetics Annual Meeting

New, groundbreaking technology delivers Illumina's most comprehensive genome yet; early results from Broad Clinical Labs demonstrate a highly simplified workflow,…

1 year ago

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated…

1 year ago

Azenta Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test

BURLINGTON, Mass., Oct. 30, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the launch of a long-read Whole Genome…

1 year ago